ndralsresearch

June 21, 2024 The last subjects for the clinical trial using FC-12738, affectionally called TVALA, had their final follow up visit on June 14. All is going well and the data will be exhaustively examined. I'm happy to say that there were no adverse events or concerns. The humans mirrored the animals studies, consistency is always good in science! The final study report will issue in a few months and we can move the studies into ALS patients. The protocol for the next study is ready, we'd...

In hindsight, Richard Helms remembered he had a non-painful limp in 2018. After multiple consults he was introduced to ALS, that was in 2019 and typical of the year it takes to get a diagnosis. We had mutual interests in race horses, flying, and books. Our shared curiosity in solving puzzles naturally led to a collaboration investigating ALS. Our nationwide search for a treatment (there were none) led to the creation of NDR in 2020. NDR's mission is identifying novel, underfunded research...

Neurodegenerative disease research is pleased to announce the progress of developing TVALA for the treatment of neuroinflammation in ALS. You can read about the trial and follow our progress .